Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a pathological Oral Glucose Tolerance Test (OGTT)

Next Previous
Trial Profile

A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a pathological Oral Glucose Tolerance Test (OGTT)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APHD-012 (Primary)
  • Indications Prediabetic state
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Aphaia Pharma

Most Recent Events

  • 20 Jun 2024 Primary endpoint has been met. (Change from baseline in AUC0-2h values of Oral Glucose Tolerance Test (OGTT) as measured in blood samples [ Time Frame: Day 1 to Day 42; Day 71 to Day 112 ]), according to an Aphaia Pharma Media Release.
  • 20 Jun 2024 Results published in an Aphaia Pharma Media Release.
  • 08 Mar 2024 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top